Compare COLL & ARI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLL | ARI |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2015 | 2009 |
| Metric | COLL | ARI |
|---|---|---|
| Price | $48.66 | $9.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $47.50 | $10.83 |
| AVG Volume (30 Days) | 494.7K | ★ 1.1M |
| Earning Date | 02-26-2026 | 02-09-2026 |
| Dividend Yield | N/A | ★ 10.25% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.63 | 0.89 |
| Revenue | ★ $757,067,000.00 | $269,296,000.00 |
| Revenue This Year | $26.35 | $25.91 |
| Revenue Next Year | $3.67 | $14.63 |
| P/E Ratio | $29.06 | ★ $11.00 |
| Revenue Growth | 26.34 | ★ 67.16 |
| 52 Week Low | $23.23 | $7.70 |
| 52 Week High | $50.79 | $11.11 |
| Indicator | COLL | ARI |
|---|---|---|
| Relative Strength Index (RSI) | 58.37 | 50.34 |
| Support Level | $44.51 | $9.64 |
| Resistance Level | $50.79 | $9.93 |
| Average True Range (ATR) | 1.45 | 0.17 |
| MACD | -0.40 | -0.01 |
| Stochastic Oscillator | 63.89 | 61.22 |
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that primarily originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.